title: Vitamin D insufficiency may impair CD4 recovery among Women's Interagency HIV Study participants with advanced disease on HAART.
abstract: BACKGROUND
  Recent studies in HIV-infected men report an association between low vitamin D (25OH-D) and CD4 recovery on HAART. We sought to test this relationship in the Women's Interagency HIV Study (WIHS).
  
  
  METHODS
  We examined 204 HIV-infected women with advanced disease, who started HAART after enrollment in the WIHS. We measured vitamin D (25OH-D) levels about 6 months prior to HAART initiation. The relationship between CD4 recovery (defined as increases of ≥50, 100, and 200 cells at 6, 12, and 24 months) and exposure variables was examined using logistic regression models at 6, 12 and 24 months post-HAART initiation in unadjusted and adjusted analyses, and using multivariable longitudinal Generalized Estimating Equations (GEE). Vitamin D insufficiency was defined as 25OH-D levels at least 30 ng/ml.
  
  
  RESULTS
  The majority were non-Hispanic black (60%) and had insufficient vitamin D levels (89%). In adjusted analyses, at 24 months after HAART, insufficient vitamin D level (OR 0.20, 95% CI 0.05-0.83) was associated with decreased odds of CD4 recovery. The undetectable viral load (OR 11.38, 95% CI 4.31-30.05) was associated with CD4 recovery. The multivariable GEE model found that average immune reconstitution attenuated significantly (P < 0.01) over time among those with insufficient vitamin D levels compared with those with sufficient vitamin D levels.
  
  
  CONCLUSIONS
  Vitamin D insufficiency is associated with diminished late CD4 recovery after HAART initiation among US women living with advanced HIV. The mechanism of this association on late CD4 recovery may be late vitamin D-associated production of naive CD4 cells during immune reconstitution.
authors.affiliation: Rush University Medical Center, Chicago, IL, USA. Mariam_aziz@rush.edu
authors.forename: Mariam
authors.initials: M
authors.lastname: Aziz
authors.forename: Britt
authors.initials: B
authors.lastname: Livak
authors.forename: Jane
authors.initials: J
authors.lastname: Burke-Miller
authors.forename: Audrey L
authors.initials: AL
authors.lastname: French
authors.forename: Marshall J
authors.initials: MJ
authors.lastname: Glesby
authors.forename: Anjali
authors.initials: A
authors.lastname: Sharma
authors.forename: Mary
authors.initials: M
authors.lastname: Young
authors.forename: Maria C
authors.initials: MC
authors.lastname: Villacres
authors.forename: Phyllis C
authors.initials: PC
authors.lastname: Tien
authors.forename: Elizabeth T
authors.initials: ET
authors.lastname: Golub
authors.forename: Mardge H
authors.initials: MH
authors.lastname: Cohen
authors.forename: Oluwatoyin M
authors.initials: OM
authors.lastname: Adeyemi
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003430:Cross-Sectional Studies; D018450:Disease Progression; D005260:Female; D006679:HIV Seropositivity / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D008875:Middle Aged; D011446:Prospective Studies; D012367:RNA, Viral; D014481:United States / Q000453:epidemiology; D019562:Viral Load; D014808:Vitamin D Deficiency / Q000097:blood / Q000276:immunology*; D016387:Women's Health
chemical_list: D012367:RNA, Viral